Interferon Therapy for Malignant Solid Tumors

被引：1
|
作者：
Warren, Katherine E. [1 ]
Young, Howard A. [2 ]
机构：
[1] Natl Canc Inst, Pediat Oncol Branch, Bldg 10 CRC,Room 1-3930, Bethesda, MD 20892 USA
[2] Ctr Canc Res, Lab Expt Immunol, Frederick, MD USA
来源：
CURRENT DRUG THERAPY | 2010年 / 5卷 / 02期
基金：
美国国家卫生研究院;
关键词：
Interferon; PEG-Intron; cytokine; cancer; malignancy; tumor; anti-tumor drugs;
D O I：
10.2174/157488510791065058
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
It has been over 50 years since the discovery of interferon. While initially touted as "the wonder drug' for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first "cytokine" in cancer therapy.
引用
收藏
页码：132 / 138
页数：7
相关论文
共 50 条
12345